Inhibrx Biosciences, Inc.
NASDAQ:INBXBiotechnology
-$2.58 today
- Market cap
- $1.02B
- Beta
- 3.32
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$8.35
Volume 0.29M
Average 0.43M
INBX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Inhibrx Biosciences, Inc.NASDAQ: INBX
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$30.93M, compared with -$42.9M a year earlier. Trailing-twelve-month operating income was -$123.05M.
Context
- Operating income amounted to 10386.5% of revenue in FY2025, down 155337.5 pp from a year earlier.
- Operating income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 2 analysts of -$125.43M (+7.1%) for the fiscal year ending Dec 2026, a slowdown from the +59.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$30.93M-0.0% QoQ
- Last fiscal yearDec 2025
- -$135.03M+59.3% YoY
- LTMMar 2026
- -$123.05M+59.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +27.9% | — | — |
| 1 year | +59.3% | +7.1% | -52.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (135.03M) USD
- Year-over-year change
- +59.3%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (135.03M) | +59.3% |
| FY2024 | 2024-12-31 | (331.45M) | -51.2% |
| FY2023 | 2023-12-31 | (219.22M) | -69.8% |
| FY2022 | 2022-12-31 | (129.12M) | -68.6% |
| FY2021 | 2021-12-31 | (76.56M) | — |
Operating Income vs competitors
How INBX compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +59.1% is the highest of 7, against a peer median of -34.4%.
- Operating income amounts to 9465.5% of revenue for INBX, versus a peer median of 737.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
TECXTectonic Therapeutic, Inc. | LTM Mar 2026 | -$93.04M USD | -46.9% | — | — |
| LTM Mar 2026 | -$123.05M USD | +59.1% | — | 9465.5% | |
| LTM Mar 2026 | -$128.54M USD | -13.6% | — | 7000.8% | |
| LTM Mar 2026 | -$156.98M USD | -38.2% | — | 726.3% | |
| LTM Mar 2026 | -€212.71M EUR | -251.5% | — | 570.3% | |
GENBGenerate Biomedicines, Inc. | FY2025 | -$235.07M USD | -19.4% | — | 737.0% |
| LTM Sep 2026 | -$334.5M USD | -30.5% | — | 298657.1% | |
| Peer median (excluding INBX) | — | -34.4% | — | 737.0% | |
Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.13M | 2.19M | 1.8M | 200K | 1.3M |
| Cost of Revenue | 2.69M | 110.19M | 1.19M | 2.29M | 2.48M |
| Gross Profit | 4.44M | (107.99M) | 609K | (2.09M) | (1.18M) |
| Gross Margin | 62.3% | -4926.7% | 33.8% | -1042.5% | -91.0% |
| Research & Development | 71.44M | 110.19M | 190.65M | 203.74M | 113.03M |
| Selling, General & Admin | 12.36M | 21.12M | 29.38M | 127.91M | 23.3M |
| Operating Expenses | 12.34M | 21.12M | 219.83M | 329.36M | 133.84M |
| Depreciation & Amortization | 1.2M | 1.23M | 1.19M | 2.29M | 2.48M |
| EBITDA | (75.37M) | (125.82M) | (206.69M) | 1.7B | (132.54M) |
| EBITDA Margin | -1057.8% | -5739.8% | -11482.9% | 851675.0% | -10195.5% |
| Operating Income | (76.56M) | (129.12M) | (219.22M) | (331.45M) | (135.03M) |
| Operating Margin | -1074.6% | -5890.4% | -12178.9% | -165724.0% | -10386.5% |
| Interest Income | 5.22M | 16.11M | 11.92M | 10.94M | 7.55M |
| Interest Expense | 5.22M | 16.11M | 31.84M | 13.49M | 12.2M |
| Other Income / Expenses | (5.2M) | (16.11M) | (20.5M) | 2.02B | (5.03M) |
| Income Before Tax | (81.77M) | (145.22M) | (239.72M) | 1.69B | (140.05M) |
| Pre-Tax Margin | -1147.6% | -6625.1% | -13318.0% | 843787.0% | -10773.3% |
| Income Tax Expense | 2K | 3K | 3K | 2K | 2K |
| Net Income | (81.77M) | (145.23M) | (241.36M) | 1.69B | (140.06M) |
| Net Margin | -1147.6% | -6625.3% | -13408.9% | 843786.0% | -10773.5% |
| EPS (Basic) | (2.15) | (3.62) | (5.12) | 116.58 | (9.04) |
| EPS (Diluted) | (2.15) | (3.62) | (5.12) | 116.58 | (9.04) |
| Weighted Avg Shares | 38.01M | 40.11M | 47.13M | 14.48M | 15.49M |
| Weighted Avg Shares (Diluted) | 38.01M | 40.11M | 47.13M | 14.48M | 15.49M |
Inhibrx Biosciences, Inc.
NASDAQ:INBX
Intrinsic Alpha fair value
Locked
Current Price
$69.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.